4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up - Time to Buy?

Key Points

• 4D Molecular Therapeutics' stock opened at $10.83 after previously closing at $10.00, with a current trading volume of 453,204 shares.
• Analyst ratings are mixed, with Chardan Capital and Royal Bank of Canada giving buy ratings and price targets of $25.00 and $26.00 respectively, while Weiss Ratings maintained a sell rating.
• The company reported a loss of ($0.98) EPS for the last quarter, missing estimates, and had a very low revenue of $0.01 million compared to expectations of $0.52 million.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report)'s stock price gapped up before the market opened on Friday . The stock had previously closed at $10.00, but opened at $10.83. 4D Molecular Therapeutics shares last traded at $10.91, with a volume of 453,204 shares changing hands.

Analyst Upgrades and Downgrades

FDMT has been the subject of several analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Friday. Chardan Capital reaffirmed a "buy" rating and issued a $25.00 price objective on shares of 4D Molecular Therapeutics in a research note on Tuesday, August 12th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $26.00 price objective on shares of 4D Molecular Therapeutics in a research note on Tuesday. Finally, Roth Capital reduced their price objective on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research note on Tuesday, August 12th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, 4D Molecular Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $29.50.

4D Molecular Therapeutics Trading Up 17.6%

The firm's fifty day moving average is $7.92 and its 200 day moving average is $5.35. The stock has a market cap of $549.01 million, a P/E ratio of -3.33 and a beta of 2.93.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative return on equity of 40.15% and a negative net margin of 594,375.81%.The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.52 million. Research analysts forecast that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Institutional Trading of 4D Molecular Therapeutics

Several institutional investors have recently made changes to their positions in the business. Farther Finance Advisors LLC boosted its position in shares of 4D Molecular Therapeutics by 117.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company's stock valued at $43,000 after acquiring an additional 2,674 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of 4D Molecular Therapeutics by 2.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 663,657 shares of the company's stock valued at $5,767,000 after acquiring an additional 14,832 shares in the last quarter. Rangeley Capital LLC acquired a new stake in shares of 4D Molecular Therapeutics during the 2nd quarter valued at about $48,000. Man Group plc boosted its position in 4D Molecular Therapeutics by 159.7% in the second quarter. Man Group plc now owns 134,932 shares of the company's stock valued at $501,000 after buying an additional 82,980 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its position in 4D Molecular Therapeutics by 128.5% in the second quarter. BNP Paribas Financial Markets now owns 63,914 shares of the company's stock valued at $237,000 after buying an additional 35,948 shares in the last quarter. 99.27% of the stock is currently owned by institutional investors and hedge funds.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.